Full video transcriptClick to expand
Auto-generated transcript of @noah.jay_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00If you're not taking CJC with your GLP3RT, you should be, because this is how you get even better
- 0:06before and after transformation results like I did from your ratatouille research on your pet rat.
- 0:11So here's how CJC plus IPA gives you better ratatouille results. It's by helping to increase
- 0:17your natural growth, production, lipolysis, and recovery, and it helps to regulate your metabolism
- 0:22better by protecting your lean mass. And that extra GH means you get better connective tissue
- 0:28which is great for the recovery of your tendons, ligaments, and muscles. Which means you recover
- 0:32from your workouts better with fewer aches and injuries. And it even improves the quality of your
- 0:37sleep so you fall asleep faster, you sleep longer, and you get better, deeper sleep. Which in turn
- 0:43gives you even better recovery so you can perform better in the gym. And the amount of sleep that
- 0:48you get determines what you look like in your before and after results. So how much lipolysis
- 0:53you experience versus your ability to maintain and even build muscle in a deficit.
- 0:58So for all your research needs use code JBERD now from my trusted third party tested and approved
- 1:04source. And as always you cannot rely on the research alone. You need to work out, you need
- 1:09to get your daily steps in, and you need to continue focusing on nutrition.
@noah.jay_'s CJC peptide claims need more evidence
Quick answer
CJC-1295 and ipamorelin act synergistically on the GH axis, with early human pharmacokinetic data supporting IGF-1 elevation, but no controlled trials have evaluated this combination specifically in patients using GLP-1 receptor agonists for weight loss. The claim that the stack preserves lean mass during GLP-1-induced caloric restriction is mechanistically plausible but lacks direct human evidence at this time. Both peptides remain unapproved for human use by the FDA and are classified as research compounds.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 12 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @noah.jay_'s CJC peptide claims need more evidence, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
@noah.jay_'s CJC peptide claims need more evidence should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@noah.jay_'s CJC peptide claims need more evidence" from Noah Jay. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: CJC-1295 and ipamorelin act synergistically on the GH axis, with early human pharmacokinetic data supporting IGF-1 elevation, but no controlled trials have evaluated this combination specifically in patients using GLP-1 receptor agonists for weight loss.
The reason this review is not generic is the source wording and the canonical claim label "peptides replying to dayneharrelson how to get better before and aft." In this clip, the useful excerpt is: "If you're not taking CJC with your GLP3RT, you should be, because this is how you get even better before and after transformation results like I did from your ratatouille research on your pet rat." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
CJC-1295 and ipamorelin act synergistically on the GH axis, with early human pharmacokinetic data supporting IGF-1 elevation, but no controlled trials have evaluated this combination specifically in patients using GLP-1 receptor agonists for weight loss.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- CJC-1295 and ipamorelin act synergistically on the GH axis, with early human pharmacokinetic data supporting IGF-1 elevation, but no controlled trials have evaluated this combination specifically in patients using GLP-1 receptor agonists for weight loss. The claim that the stack preserves lean mass during GLP-1-induced caloric restriction is mechanistically plausible but lacks direct human evidence at this time. Both peptides remain unapproved for human use by the FDA and are classified as research compounds.
- CJC-1295 elevated IGF-1 dose-dependently in healthy adults per Teichman et al. (2006, JCEM), confirming the GH-stimulating mechanism, but this was a pharmacokinetic study, not a body composition or transformation trial.
- No peer-reviewed human trials have specifically tested CJC-1295 plus ipamorelin alongside GLP-1 receptor agonists for fat loss or lean mass preservation.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- CJC-1295 elevated IGF-1 dose-dependently in healthy adults per Teichman et al. (2006, JCEM), confirming the GH-stimulating mechanism, but this was a pharmacokinetic study, not a body composition or transformation trial.
- No peer-reviewed human trials have specifically tested CJC-1295 plus ipamorelin alongside GLP-1 receptor agonists for fat loss or lean mass preservation.
- GH's role in tendon collagen synthesis has clinical support from Doessing et al. (2010, Journal of Physiology), making the connective tissue recovery claim the strongest individual claim in the video.
- The 'pet rat' and 'ratatouille research' framing is a legal workaround for selling unapproved compounds for human use, not a genuine research disclaimer.
- Resistance training and protein intake remain the highest-evidence interventions for muscle preservation during GLP-1-induced weight loss, ahead of any peptide secretagogue stack.
- Neither CJC-1295 nor ipamorelin is FDA-approved for any human indication, and 'third-party tested' does not confer regulatory approval or guarantee product safety.
- GH axis manipulation in non-GH-deficient individuals carries potential risks including insulin resistance and theoretical proliferative effects that require physician oversight, none of which are addressed in the video.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @noah.jay_ actually say?
The creator argues that stacking CJC-1295 and ipamorelin alongside a GLP-1 receptor agonist produces better body composition results by boosting growth hormone output, accelerating fat breakdown, protecting muscle, improving connective tissue recovery, and enhancing sleep quality. He frames this as advice for getting better "before and after transformation results" and directs viewers to a third-party-tested source using a promo code. He also uses the recurring "pet rat" and "ratatouille research" framing, which is the standard social media workaround for selling peptides without explicitly claiming human use.
To be direct: this is a commercial pitch dressed up as fitness education. The research framing is a legal fig leaf. The actual audience is people on semaglutide or tirzepatide who want to look better in photos, and the creator knows it.
Does the science back this up?
Some of it, yes, but the evidence base is weaker and more conditional than the video implies. CJC-1295 is a growth hormone-releasing hormone analogue, and ipamorelin is a selective ghrelin receptor agonist. Together they produce a synergistic pulse of GH secretion. That mechanism is real and reasonably well-documented in early clinical work.
Teichman et al. (2006, Journal of Clinical Endocrinology and Metabolism) showed CJC-1295 dose-dependently elevated IGF-1 levels in healthy adults over multiple weeks. Bowers et al. (1990, Endocrinology) and subsequent work confirmed ipamorelin's selective GH-releasing profile with minimal cortisol or prolactin spillover compared to older secretagogues. The lipolysis claim has some mechanistic support since GH promotes fatty acid mobilization, but whether this translates to meaningful fat loss in non-GH-deficient adults taking a GLP-1 agonist is a different and largely unstudied question. No peer-reviewed trials have specifically tested this combination in humans for aesthetic body composition outcomes.
What did they get wrong (or right)?
Credit where it is due: the claim that GH supports connective tissue repair is legitimate. Doessing et al. (2010, Journal of Physiology) demonstrated that GH administration increased collagen synthesis in tendon tissue in recreational athletes. The sleep quality angle also has real support. Frieboes et al. (1995, Sleep) documented that GHRH administration promoted slow-wave sleep in humans, and ipamorelin's GH pulse timing around sleep onset is pharmacologically sensible.
Where he oversells: the idea that adding CJC and ipamorelin to a GLP-1 meaningfully changes "before and after" photos is speculative marketing, not established science. GLP-1 agonists already have a muscle-loss problem, and secretagogues are being studied as a mitigation strategy, but the data is preliminary. Lundberg et al. (2021, Obesity Reviews) noted muscle preservation during GLP-1-induced weight loss remains an open clinical challenge. Presenting this combo as a proven transformation enhancer without that context is misleading.
What should you actually know?
CJC-1295 and ipamorelin are not FDA-approved for any indication in humans. They are sold under research chemical exemptions, which is why the creator uses the pet rat framing. That framing does not change what the audience is buying or why. "Third-party tested and approved" is a marketing phrase, not a regulatory status. It tells you nothing about purity standards, sterility, or dosing accuracy in any particular batch.
If you are on a GLP-1 agonist and concerned about muscle loss, the interventions with the strongest evidence are resistance training and adequate protein intake, as confirmed by Biolo et al. (1997, American Journal of Physiology) and more recent GLP-1-specific work. Peptide secretagogues may have a supporting role, but they sit well behind those fundamentals in the evidence hierarchy. Anyone considering them should do so under physician supervision, particularly because GH axis manipulation carries cardiovascular, metabolic, and oncological considerations that a TikTok promo code does not address.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Noah Jay · TikTok creator
30.1K views on this video
Replying to @dayneharrelson how to get better before and after transformation results from your cjc ipa and glp. Use code Jaybird from my trusted 3rd party tested and approved source. #beforeandafter
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about cjc-1295 elevated igf-1 dose-dependently in healthy adults per teichman et?
CJC-1295 elevated IGF-1 dose-dependently in healthy adults per Teichman et al. (2006, JCEM), confirming the GH-stimulating mechanism, but this was a pharmacokinetic study, not a body composition or transformation trial.
What does the video say about no peer-reviewed human trials have specifically tested cjc-1295 plus ipamorelin?
No peer-reviewed human trials have specifically tested CJC-1295 plus ipamorelin alongside GLP-1 receptor agonists for fat loss or lean mass preservation.
What does the video say about gh's role in tendon collagen synthesis has clinical support from?
GH's role in tendon collagen synthesis has clinical support from Doessing et al. (2010, Journal of Physiology), making the connective tissue recovery claim the strongest individual claim in the video.
What does the video say about the 'pet rat'?
The 'pet rat' and 'ratatouille research' framing is a legal workaround for selling unapproved compounds for human use, not a genuine research disclaimer.
What does the video say about resistance training?
Resistance training and protein intake remain the highest-evidence interventions for muscle preservation during GLP-1-induced weight loss, ahead of any peptide secretagogue stack.
What does the video say about neither cjc-1295 nor ipamorelin?
Neither CJC-1295 nor ipamorelin is FDA-approved for any human indication, and 'third-party tested' does not confer regulatory approval or guarantee product safety.
Sources & references
- [1]Teichman et al. (2006)
- [2]Bowers et al. (1990)
- [3]Doessing et al. (2010)
- [4]Frieboes et al. (1995)
- [5]Lundberg et al. (2021)
- [6]Biolo et al. (1997)
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Noah Jay, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.